ENGN Key Statistics, Chart & Performance
The current stock price of ENGN is 9.04 USD. In the past month the price increased by 12.02%. In the past year, price increased by 13.28%.
ENGN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.43 | 407.98B | ||
| AMGN | AMGEN INC | 15.07 | 177.50B | ||
| GILD | GILEAD SCIENCES INC | 15.25 | 154.97B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.49 | 116.66B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.34 | 82.03B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 782 | 52.69B | ||
| INSM | INSMED INC | N/A | 37.61B | ||
| NTRA | NATERA INC | N/A | 31.92B | ||
| BIIB | BIOGEN INC | 10.56 | 25.94B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.06 | 21.65B | ||
| INCY | INCYTE CORP | 15.47 | 19.49B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.34B |
Related stock screener links
About ENGN
Company Profile
enGene Holdings, Inc. is a clinical-stage biotechnology company, which engages in developing gene therapies. The company is headquartered in Saint-Laurent, Quebec and currently employs 56 full-time employees. The company went IPO on 2021-12-10. The Company’s lead program is detalimogene voraplasmid, (detalimogene) for patients with non-muscle invasive bladder cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase II study, which includes a cohort studying detalimogene in Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (Cis). Detalimogene is being developed through its proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including DNA and various forms of RNA. The firm is developing non-viral genetic medicines based on its DDX gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
Company Info
ENGENE HOLDINGS INC
4868 Rue Levy, Suite 220
Saint-Laurent QUEBEC CA
Employees: 57
Phone: 15143324888
ENGENE HOLDINGS INC / ENGN FAQ
What does ENGN do?
enGene Holdings, Inc. is a clinical-stage biotechnology company, which engages in developing gene therapies. The company is headquartered in Saint-Laurent, Quebec and currently employs 56 full-time employees. The company went IPO on 2021-12-10. The Company’s lead program is detalimogene voraplasmid, (detalimogene) for patients with non-muscle invasive bladder cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase II study, which includes a cohort studying detalimogene in Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (Cis). Detalimogene is being developed through its proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including DNA and various forms of RNA. The firm is developing non-viral genetic medicines based on its DDX gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
Can you provide the latest stock price for ENGENE HOLDINGS INC?
The current stock price of ENGN is 9.04 USD. The price decreased by -4.84% in the last trading session.
Does ENGENE HOLDINGS INC pay dividends?
ENGN does not pay a dividend.
What is the ChartMill rating of ENGENE HOLDINGS INC stock?
ENGN has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the GICS sector and industry of ENGN stock?
ENGENE HOLDINGS INC (ENGN) operates in the Health Care sector and the Biotechnology industry.
Can you provide the upcoming earnings date for ENGENE HOLDINGS INC?
ENGENE HOLDINGS INC (ENGN) will report earnings on 2026-03-02.
ENGN Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to ENGN. When comparing the yearly performance of all stocks, ENGN is one of the better performing stocks in the market, outperforming 80.42% of all stocks.
ENGN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ENGN. ENGN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
ENGN Financial Highlights
Over the last trailing twelve months ENGN reported a non-GAAP Earnings per Share(EPS) of -2.29.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -38.58% | ||
| ROE | -47.2% | ||
| Debt/Equity | 0.09 |
ENGN Forecast & Estimates
17 analysts have analysed ENGN and the average price target is 24.2 USD. This implies a price increase of 167.72% is expected in the next year compared to the current price of 9.04.